Basic Protopic Information

• INN (International Nonproprietary Name): Tacrolimus
• Brand Names Available In Australia: Protopic (originator), imported generics such as Tacrolimus Sandoz and Talimus may appear depending on supplier and registration; availability varies by market and supplier agreements.
• ATC Code: D11AH01 — Tacrolimus (Topical Calcineurin Inhibitors).
• Forms & Dosages: Ointment 0.03% (children ≥2 years and adults) and ointment 0.1% (adolescents ≥16 years and adults); commonly supplied in tubes (typical sizes include 30 g and 60 g depending on market).
• Manufacturers In Australia: Astellas Pharma is the originator; generic manufacturers active internationally include Sandoz, Glenmark, Intas, Cipla and Emcure; local availability depends on registration and supplier importation.
• Registration Status In Australia: Tacrolimus topical formulations are registered in multiple jurisdictions and are prescription only in virtually all markets; clinicians should confirm current TGA product listings and local registration for specific brands.
• OTC / Rx Classification: Prescription only (Rx) — not available over the counter.

Latest Research Highlights

Worried about long‑term safety and whether tacrolimus actually works faster than steroids?

Recent trials and cohort studies from 2022–2024 continue to support topical tacrolimus as an effective non‑steroidal option for moderate‑to‑severe atopic dermatitis, with many patients reporting symptom relief within days to weeks.

Longitudinal safety data including open‑label extensions up to four years show low systemic absorption and a consistent adverse‑effect profile dominated by transient local burning or stinging.

Regulatory agencies including the FDA, EMA and TGA retain prescription‑only status and include precautionary label language about use in the immunocompromised and a theoretical malignancy signal; these are warnings rather than proven causal statements.

Data Highlight: Australian TGA adverse‑event reports match international safety patterns, and no new class‑wide safety contraindications have emerged since 2022.

Clinical Effectiveness In Australia

Are Australian dermatologists actually using tacrolimus, and what does it change for patients?

Tacrolimus ointment (Protopic and imported generics) is commonly used in Australia where topical corticosteroids are unsuitable — notably on the face, eyelids and flexures — or as a steroid‑sparing maintenance option.

TGA registration mirrors FDA and EMA indications: treatment for moderate‑to‑severe atopic dermatitis in patients from age 2 upward with strength selection guided by age and severity.

Real‑world audits in Australia show measurable reductions in the potency and duration of topical corticosteroids used, and fewer episodes of steroid‑related skin atrophy when tacrolimus replaces prolonged steroid use on sensitive areas.

PBS And Pricing Note: Tacrolimus topical formulations are prescription‑only and subsidy through the Pharmaceutical Benefits Scheme varies by formulation and indication.

Clinicians and patients should confirm the current PBS status for subsidised access because some formulations or indications may not be listed and private purchase through pharmacies could apply.

Indications And Expanded Uses

When should tacrolimus be used and where do Australian clinics go off‑label?

On‑label per TGA and international SPCs, tacrolimus ointment is indicated for moderate‑to‑severe atopic dermatitis in patients aged two years and older.

Dosage guidance is age‑stratified: 0.03% for children from two years; 0.03% and 0.1% options for adolescents ≥16 and adults as clinically indicated.

• Labelled Indications: Moderate‑to‑severe atopic dermatitis from age 2; apply a thin layer twice daily until clear; maintenance once or twice weekly at recurrent sites.
• Common Off‑Label Uses In Australia: Short‑term management of steroid‑dependent facial eczema, peri‑ocular dermatitis under close supervision, and specialist use in inverse/intertriginous eczema where steroid atrophy risk is high.

Off‑label prescribing should be documented and discussed with the patient, particularly where PBS subsidy does not apply and private cost is relevant.

Clinical Decision Checklist:

• Confirm age and choose appropriate strength (0.03% for 2–15 years; 0.03% or 0.1% ≥16 years).
• Assess for active skin infection before starting.
• Discuss transient stinging and maintenance regimen options.
• Document off‑label rationale and PBS implications if applicable.

Composition And Brand Landscape

What exactly is in the tube and which brands might you see at the pharmacy?

Tacrolimus is the active ingredient (INN) and is a topical calcineurin inhibitor classified under ATC code D11AH01.

The marketed vehicle is an ointment — there is no licensed topical cream formulation for tacrolimus in the data provided.

Excipients And Packaging Notes: Ointment vehicles commonly include mineral oil and paraffin.

Availability of generics in Australia depends on importation, registration and supplier agreements; community pharmacies may substitute generics when available.

Contraindications And Special Precautions

Who should avoid tacrolimus, and which patients need closer monitoring?

Absolute Contraindications: known hypersensitivity to tacrolimus or any ointment excipient, active skin infection at the application site, and severely immunocompromised patients such as post‑transplant patients or those on systemic immunosuppression.

Special Precautions: monitor the elderly for altered skin barrier and comorbidities; avoid routine use in pregnancy and lactation unless the treating clinician judges benefits outweigh risks and this discussion is documented.

For Indigenous and other marginalised populations consider access barriers, higher prevalence of comorbid skin infections and provide culturally safe counselling and engagement with community health services.

Family history of skin cancer or premalignant lesions is a relative concern; minimise UV exposure and monitor suspicious lesions during treatment.

Daily‑Life Cautions: do not use occlusive dressings, avoid mucous membranes, and avoid applying immediately before activities where transient burning might distract the patient (for example, handling hot objects).

Monitoring Checklist:

• Screen for immunosuppression or systemic immunosuppressant therapy before initiation.
• Check for active herpes simplex or bacterial infection at the site.
• Advise sun protection and report persistent irritation or new lesions promptly.

Dosage Guidelines

How do you use tacrolimus safely — and what if a dose is missed?

Standard Regimens: Apply a thin layer to affected areas twice daily until lesions clear, which is usually within 1–3 weeks.

For children aged 2–15 years use 0.03% ointment only.

Adults and adolescents ≥16 years may use 0.03% or 0.1% according to severity and prescriber judgement.

For maintenance some guidelines support once‑ or twice‑weekly application to previously affected areas to reduce recurrences.

No routine systemic dose adjustments are required for hepatic or renal impairment because systemic absorption is minimal, but exercise caution when applying to very thin or extensively compromised skin.

If a dose is missed, apply when remembered unless it is near the time for the next application — do not double up doses.

In the unlikely event of large accidental ingestion, seek medical help as systemic toxicity from topical tacrolimus is rare.

Interactions Overview

Will tacrolimus ointment react with my other medicines or alcohol?

Systemic drug interactions are minimal with topical tacrolimus because systemic absorption is low in standard use.

Use caution if large surface areas are treated, if applied to broken skin or if the patient is taking potent systemic CYP3A4 inhibitors, since in rare cases systemic exposure could rise.

Avoid combining topical tacrolimus with systemic immunosuppressants without specialist oversight.

There are no clinically significant interactions with food or alcohol reported for topical application, although some patients describe transient flushing or sensitivity after alcohol ingestion post‑application.

TGA adverse‑event reporting from 2022–2024 continues to show mostly local irritation and rare infection flares; clinicians and pharmacists should report suspected serious interactions or unexpected events via the TGA online form.

When To Contact A Specialist: if a patient develops systemic symptoms, extensive secondary infection, or unexplained skin lesions while on tacrolimus.

Cultural Perceptions And Patient Habits

What do Australians say about tacrolimus on forums, and how does access differ between rural and urban areas?

Many Australian patients describe tacrolimus as a “steroid‑free” option and prefer it for facial and long‑term care, though early burning on application is commonly reported in support groups and forums.

Price sensitivity is high; patients often ask about PBS subsidy, generic alternatives and online pharmacy pricing before committing to long courses.

Urban patients tend to access dermatologists and clinic samples more readily, while rural patients usually rely on GPs and community pharmacists and may use telehealth e‑prescriptions for convenience.

Supply delays or higher out‑of‑pocket costs can limit sustained therapy in remote areas, so pharmacists should proactively discuss access options, mail order and storage guidance for deliveries to rural addresses.

For Indigenous Australians provide culturally safe counselling, involve Aboriginal health services and screen actively for comorbid scabies or bacterial skin infections that can complicate eczema treatment.

Pharmacist Talking Points:

• Explain steroid‑sparing rationale and likely time to improvement (days–weeks).
• Warn about transient burning and how to manage it.
• Check PBS eligibility and offer options for generics or telehealth prescriptions if cost is a barrier.

Availability And Pricing Patterns

Where can patients get Protopic in Australia and what will it cost?

Protopic and tacrolimus ointment are prescription‑only in Australia and can be supplied through major chains such as Chemist Warehouse, Priceline, TerryWhite Chemmart and independent community pharmacies depending on stock and supplier arrangements.

Availability of the originator versus imported generic brands varies; some pharmacies will substitute generic tacrolimus when available and permitted by the prescriber.

PBS listing determines the subsidised cost for eligible patients and may differ by strength or indication.

Private pricing varies between chains and online pharmacies, so patients are price‑sensitive and commonly compare retail pharmacies or seek generic alternatives.

Telehealth services commonly provide e‑prescriptions that patients can have sent to a nominated pharmacy for collection or home delivery; rural patients should check local delivery options and storage guidance to ensure product integrity.

In our online pharmacy, protopic is available with discreet delivery to Australia in 5–14 days.

Comparable Medicines And Preferences

Which treatments are considered alternatives and how do they compare?

Main alternatives in Australian practice include topical corticosteroids (first‑line for acute flares), pimecrolimus cream (Elidel) as another topical calcineurin inhibitor, and crisaborole for mild‑to‑moderate disease.

Systemic biologics such as dupilumab and oral immunosuppressants are reserved for severe or refractory disease under specialist care.

Frequently Asked Questions

Can I buy Protopic without a prescription in Australia?

No.

Tacrolimus ointment is prescription‑only under TGA classification and must be supplied on a valid prescription; PBS subsidy depends on the product and indication.

Can I use tacrolimus on my face or eyelids?

Yes.

Tacrolimus is often preferred over topical steroids for sensitive facial skin to reduce the risk of steroid‑induced atrophy, although transient stinging is common and care should be taken to avoid the eyes and mucous membranes.

Is tacrolimus safe for children?

Tacrolimus ointment is approved from age 2 using the 0.03% strength.

It is not approved for children under two years and parents should discuss benefits and risks with their GP or paediatrician.

How should I store tacrolimus ointment?

Store below 25°C, protect from light and keep the tube tightly closed.

Check the package insert for shelf life; typically unopened product has a multi‑year shelf life and an opened tube has guidance on months of use.

Guidelines For Proper Use

What should a pharmacist tell a patient starting tacrolimus?

Demonstrate the correct amount using a pea‑sized analogy for small areas and explain that a thin layer applied twice daily is the typical initial approach.

Explain transient burning or stinging and advise patients to continue if it is mild and short‑lived, but to stop and seek review for severe or persistent irritation.

Warn against occlusive dressings and application to mucous membranes or open wounds, and remind patients not to use it concurrently with other topical immunosuppressants unless directed.

Screen for immunosuppression, active infection, pregnancy and breastfeeding before supply.

Discuss PBS eligibility, generic options and telehealth prescription logistics for rural patients, and provide culturally appropriate resources and referral to Aboriginal health services when relevant.

Counselling Checklist For Pharmacists:

• Confirm age and appropriate strength.
• Show the amount to apply and frequency.
• Advise storage, sun protection and when to seek medical review.
• Document PBS discussion and any off‑label use counselling.

Delivery Across Australia

Closing Practical Tips

Keep a simple log of application sites and symptom changes during the first month to help the prescriber assess response and tolerability.

Encourage patients to bring tubes to review appointments so pharmacists and doctors can check expiry and discuss ongoing need, maintenance schedules and possible step‑down strategies.

Report any serious or unexpected adverse events to the TGA to contribute to ongoing safety surveillance.

When in doubt, patients should be referred back to their GP or dermatologist for specialist assessment rather than prolonging unsupervised use.